Molecular diagnostics firm Inflammatix has received a $12.1 million contract extension from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a test that characterizes infections.
The company's third tranche of funding from BARDA is part of a contract worth up to $72 million if all options are exercised. Inflammatix said it would use the funds for ongoing development and clinical studies of its ViraBac EZ acute infection test, which determines whether a suspected infection is bacterial or viral based on gene expression patterns in the immune system.
In addition, the funding will also support development of the machine learning-based, point-of-care system on which ViraBac EZ and all Inflammatix tests are run, according to the vendor. BARDA is part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response.
